Fintel reports that on March 16, 2026, Jefferies downgraded their outlook for Incyte (NasdaqGS:INCY) from Buy to Hold. Analyst Price Forecast Suggests 17.55% Upside As of February 25, 2026, the ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting ...

Check out some of the companies making the biggest moves midday: Amentum Holdings — The defense contractor tumbled about 12% after fiscal first-quarter revenue and adjusted EBITDA missed Wall Street ...

Fintel reports that on October 29, 2025, Truist Securities reiterated coverage of Incyte (NasdaqGS:INCY) with a Hold recommendation. Analyst Price Forecast Suggests 2.86% Downside As of October 28, ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday. Other ...

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Incyte Corporation is one of them. Incyte Corporation (NASDAQ:INCY), a global biopharmaceutical ...

Incyte INCY is set to give its latest quarterly earnings report on Tuesday, 2025-07-29. Here's what investors need to know before the announcement. Analysts estimate that Incyte will report an ...

Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode. [Operator ...